Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Lecia V. Sequist(Taipei Veterans General Hospital), D. Ross Camidge(Odense University Hospital), Mitch Raponi(Clovis Oncology (United States)), Jeffrey D. Isaacson, Jean‐Charles Soria(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Chris Karlovich(Clovis Oncology (United States)), Shirish M. Gadgeel(Chinese University of Hong Kong), Cathy Galasso(Wayne State University), Joel W. Neal(Cancer Institute (WIA)), Robert C. Doebele(University of Colorado Anschutz Medical Campus), Heather A. Wakelee(Cancer Institute (WIA)), Jonathan W. Goldman(University of California, Los Angeles), Sarah Jaw‐Tsai(Clovis Oncology (United States)), Melody Mendenhall(University of California, Los Angeles), Geoffrey R. Oxnard(Boston Medical Center), Benjamin Solomon(Peter MacCallum Cancer Centre), Dara L. Aisner(University of Colorado System), Rafał Dziadziuszko(Gdańsk Medical University), Edward B. Garon(University of California, Los Angeles), Rebecca S. Heist(Harvard University), Andrew R. Allen(Clovis Oncology (United States)), Zofia Piotrowska(Massachusetts General Hospital), Darrin Despain(Clovis Oncology (United States)), Andréa Varga(Institut Gustave Roussy), Antoinette J. Wozniak(Wayne State University), Jennifer Logan(Massachusetts General Hospital), Lindsey Rolfe, Vassiliki A. Papadimitrakopoulou(The University of Texas MD Anderson Cancer Center), Suzanne Nichols(University of California, Los Angeles), Shannon Matheny(Clovis Oncology (United States))
Cited by 664
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k